Efficacy and Safety of the Dual SGLT1 and SGLT2 Inhibitor JP-2266 in Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study

Diabetes & Metabolism Journal · Published 2026-07-29 · DOI 10.4093/dmj.2025.1152

Free full text

Authors (10)

Eun Young Lee, Kyung Ah Han, Soo Heon Kwak, Jun Hwa Hong, You-Cheol Hwang, Gwanpyo Koh, Jing W. Hughes, Soomee Kim, Chang-Seok Lee, Bong-Soo Cha

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Lee, E., Han, K., Kwak, S., et al. (2026). Efficacy and Safety of the Dual SGLT1 and SGLT2 Inhibitor JP-2266 in Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study. Diabetes & Metabolism Journal. https://doi.org/10.4093/dmj.2025.1152

Related articles